### **Company Overview** Abbott India Limited is a leading Indian pharmaceutical company and a wholly-owned subsidiary of Abbott Laboratories, USA. With a legacy dating back to 1944, Abbott India operates exclusively in the pharmaceuticals segment and is recognized as one of India’s fastest-growing pharma companies. The company offers a diversified portfolio of over 125 science-based branded products across key therapeutic areas, including **Gastroenterology, Women's Health, Metabolics, Central Nervous System (CNS), Vaccines, and Multi-Specialty**. Abbott India is headquartered in Mumbai and operates a state-of-the-art manufacturing facility in Goa, ensuring adherence to global quality and safety standards through compliance with Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) norms. The company is a market leader in multiple therapeutic segments and plays a pivotal role in advancing preventive and comprehensive health solutions in India. --- ### **Market Position & Competitive Strengths** - **Market Leadership**: Abbott India has 16 brands ranked either #1 or #2 in their respective therapeutic categories. Eight of its brands feature among the top 100, and 10 are within the top 300 of the Indian Pharmaceutical Market (IPM), according to IQVIA data. - **Top Performing Brands**: Key flagship brands include **Udiliv (liver health), Duphalac (constipation), Cremaffin/Cremaffin Plus (laxatives), Digene (antacids), Creon (pancreatic insufficiency), Vertin (vertigo), Thyronorm (hypothyroidism), Duphaston (women’s health), Brufen (pain), Arachitol (vitamin D), and Zolfresh (insomnia)**. - **Revenue Drivers**: The top 15 brands contribute over 80% of the company’s revenue, underscoring their strategic importance and strong customer loyalty. --- ### **Therapeutic Area Highlights** #### **1. Gastroenterology (GI)** - **Market Leader**: Abbott maintains leadership in the GI space with a 38% market share in the laxatives category and strong presence across antacids and gut health. - **Growth**: The GI portfolio grew **15.9% in FY 2024–25**, up from 10% in FY 2023–24, driven by brands like **Udiliv, Duphalac, Cremaffin Plus, Digene, and Creon**. - **Innovation**: - Launched **Vonefi (Vonoprazan)**, a Potassium-Competitive Acid Blocker (PCAB), offering once-daily dosing and complete 24-hour acid control—positioned as a best-in-class therapy for severe acid-related disorders. - Introduced **Vonoprazan** through a strategic collaboration with Takeda, making Abbott one of the first to commercialize this new class of drug in India. - Enhanced Digeraft line with **Digeraft Tablet**, and launched **Digene Insta On The Go**, a convenient, portable format for on-the-go acid relief. - **Consumerization**: Hybrid promotion model for Digene and Cremaffin to balance consumer reach with ethical promotion. --- #### **2. Women’s Health** - **Flagship Brand**: **Duphaston** remains the #1 dydrogesterone brand despite intense generic competition. - **Menopause Focus**: Abbott is actively shaping the menopause care landscape through dedicated initiatives: - Launched **Femoston** and **Femoston Mini**. - Ran the “Next Chapter” campaign, including a published book of real-life stories, and established over 500 menopause clinics. - Introduced the **Pausetive Talk** multilingual education program and the **‘Tender Love & Care’** patient support program. - **Recent Launch**: **Duphaston OD** (March 2025), aimed at improving patient compliance. --- #### **3. Multi-Specialty Division** - **Growth**: The segment grew **5.8% in FY 2024–25**, up from 4.7% in 2022–23, led by **Zolfresh, Arachitol, Brufen, and Duvadilan**. - **Product Launches**: - **Citrosoda UTI** (May 2024) – a new offering for urinary tract health. - **Brufen Powergel**, **Brufen P (Ibuprofen + Paracetamol)**, and **Brufen Power Spray** for localized pain. - **Public Health Initiatives**: - ‘D Strong Active Life’ and ‘Sleep Well Wake-Up Fresh’ campaigns to raise awareness on Vitamin D and sleep health. - Launch of India’s first **online sleep score tool**, used by nearly 100,000 individuals. --- #### **4. Vaccines** - **Key Product**: **Influvac Quadrivalent** for influenza prevention. - **New Launch**: **PneumoShield 14** (November 2024), a pneumococcal conjugate vaccine to protect children under five from invasive pneumococcal disease. - **Focus Areas**: Expanding adult immunization through dedicated initiatives and targeting high-risk populations with comorbidities. --- #### **5. Metabolics** - **Thyroid Leadership**: **Thyronorm** is a market leader in hypothyroidism treatment. - **Innovation**: Launched **Linorma T3**, India’s first Liothyronine tablet, and **Thyrowel Plus** with enhanced selenium content. - **Packaging**: Introduced smart, flip-top packaging with anti-counterfeiting features and dosage control. --- #### **6. Central Nervous System (CNS)** - **Vertin** leads the vertigo space, supported by **Vertigo Coach app** and **Vertin MDS (mouth-dissolving strip)**. - **Growth Drivers**: Effective lifecycle management and therapy-shaping campaigns. - **Other Products**: Lacoxa (epilepsy), Brivetoin, and Prothiaden (depression/pain). --- ### **Strategic Pillars & Innovation** #### **1. "Beyond the Pill" Approach** Abbott is transforming from a traditional pharma player into a **comprehensive health solutions provider**: - **Udiliv as a Liver Health Solution**: Combines medication with Liver Function Tests (LFTs), Fibroscan access, and point-of-care testing for Dengue. - **Electrogastrogram (EGG) Services**: Launched to improve diagnosis of gut motility disorders. - **Gutfit Program**: One of India’s largest virtual lifestyle management programs, now available via app in 9 languages for 17 GI-related conditions. #### **2. New Product Innovation** - **7 new products launched in FY 2024–25**, including **Vonefi, Digeraft Tablet, Digene On The Go, PneumoShield 14, and Citrosoda UTI**. - **104 total new product launches since 2020**, including 4 first-to-market products developed at Abbott’s Mumbai innovation center. - Focus on **post-patent opportunities**, rapidly launching affordable generics and differentiated formulations. #### **3. Digital & Phygital Transformation** - **Digitally Empowered Sales Force**: Over 3,100 sales representatives leverage e-detailing, iPad-based tools, and digital content for HCP engagement. - **Phygital Training**: 2,600+ field staff certified through a three-tier digital-physical hybrid program. - **Digital Platforms**: - **a:care** – integrated patient support app. - **HCP-facing applications** and **Digital Command Centers** utilizing real-time social data. - **Online self-screening tools** for sleep and liver health. --- ### **Geographic & Operational Reach** - **Distribution Network**: 8,100+ stockists, ensuring presence across millions of retail and institutional outlets. - **Manufacturing**: State-of-the-art plant in **Goa** produces ~20% of the company’s volume and supports consistent supply. - **Infrastructure Excellence**: - **Barwala Stamping Facility**: GMP-compliant, reduces institutional order delivery time from 45 to 7 days. - **Online Temperature Monitoring System (OTMS)**: Ensures cold-chain integrity across warehouses. --- ### **Sustainability & Social Impact** - **SEWA Partnership**: Collaborates with the Self-Employed Women’s Association across 43 districts to deliver NCD screening, diagnosis, and treatment via community clinics and telemedicine, reaching over **140,000 patients** and empowering hundreds of women health workers. - **Public Health Initiatives**: - CT scan installation at BHU’s Trauma Center (Varanasi). - Nationwide vaccination drives for healthcare workers. - Scientific collaborations with leading Indian institutions and research bodies. --- ### **Strategic Priorities (2025)** 1. **Accelerate Growth of Pillar Brands** through lifecycle management and therapy-shaping. 2. **Deepen “Beyond-the-Pill” Portfolios** with digital diagnostics, awareness platforms, and patient support. 3. **Expand Portfolio in High-Growth Areas** like gut health, menopause, adult vaccines, and CNS. 4. **Scale Hybrid Promotion Models** for OTC brands. 5. **Strengthen HCP Engagement** via multi-channel, data-driven platforms. 6. **Build Mega Brands** by transforming base brands through innovation and omnichannel marketing. ---